Before joining the University of Maine School of Law, Emily Michiko Morris spent a year working in China as an Eastern Scholar and visiting professor at the Shanghai University of Political Science and Law. She was invited to the Shanghai University to establish a collaborative program on intellectual property law and comparative law. Professor Morris specializes in patent law, particularly as it relates to biotechnology, the pharmaceutical industry, and university research. Her other research interests include comparative Japanese and Chinese intellectual property law.

Professor Morris currently teaches in the areas of intellectual property law, comparative law, food and drug law, bioethics, and contracts. She has also taught Japanese law and a number of other intellectual property courses as an Associate Professor at the Indiana University Robert H. McKinney School of Law, a Visiting Associate Professor at the Chicago-Kent College of Law, and as an adjunct professor and Humphrey Fellow in Law and Economic Policy at the John M. Olin Center for Law and Economics, University of Michigan Law School. She has published a number of law review articles on patentable subject matter, the Hatch-Waxman Act, and the Bayh-Dole Act, as well as on the effects of patent claim construction and scope on incentives and innovation. She has also contributed to the Comparative Law Prof Blog on topics such as Chinese patent litigation patterns, Chinese video game copyright suits, Chinese trademark suits, comparative IP law, and Indian pharmaceutical patents.

Professor Morris earned her A.B., magna cum laude, from Harvard University and her J.D., magna cum laude, from the University of Michigan Law School, where she was an articles editor on the Michigan Law Review. After law school, Professor Morris clerked for the Honorable Bruce M. Selya on the U.S. Court of Appeals for the First Circuit, and then worked for three years as an associate in the Issues & Appeals section of the Washington, D.C. office of Jones Day.

Selected Publications:

“Zombification” Myths v. Real Effective Patent Lives in Pharma, __ FLA. L. REV. __ (forthcoming).

Much Ado About the TPP’s Effect on Pharmaceuticals, 20 J. ECON. L. & MGMT. 135 (symposium issue) (2017) [SSRN] [PDF]

The Irrelevance of Nanotechnology Patents, 49 CONN. L. REV. 499 (2016). [SSRN] [PDF]

The Many Faces of Bayh-Dole, 54 DUQ. L. REV. 81 (2016). [SSRN]

Alice, Artifice, and Action – and Ultramercial, PATENTLY-O: PATENT POSTS (July 8, 2014). [Patentlyo]

Intuitive Patenting, 66 S.C. L. REV. 61 (2014). [SSRN]

What Is “Technology”?, 20 B.U. J. SCI. & TECH. L. 24 (2014). [SSRN]

Res or Rules? Patents and the (Uncertain) Rules of the Game, 18 MICH. TELECOMM. & TECHN. L. REV. 481 (2012). [SSRN]

The Myth of Generic Pharmaceutical Competition Under the Hatch-Waxman Act, 22 FORDHAM INTELL. PROP. MEDIA & ENT. L.J. 245 (2012). [SSRN]

The Tragedy of the Condominiums: Legal Responses to Collective Action Problems After the Kobe Earthquake, 51 AM. J. COMP. L. 903 (2003) (with Mark D. West) (recipient of the Hessel Yntema Prize from the American Society of Comparative Law). [SSRN]